Gilead Sciences, Inc (GIS) Stock Price & News

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia

About Gilead Sciences, Inc

CEOდენიელ ო'დეი

Employees17 ათ.

Founded22 ივნ. 1987

HeadquartersFoster City, კალიფორნია, ამერიკის შეერთებული შტატები

Sector-

Websitegilead.com

All values in USD	სექ. 2025	დეკ. 2025	მარ. 2026	ივნ. 2026
Revenue	-	-	-	-
Cost of goods sold	-	-	-	-
Cost of revenue	-	-	-	-
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	-	-	-	-
Operating expense	-	-	-	-
Total operating expenses	-	-	-	-
Operating income	-	-	-	-
Other non operating income	-	-	-	-
EBT including unusual items	-	-	-	-
EBT excluding unusual items	-	-	-	-
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-	-	-	-
Net profit margin	39,28%	27,55%	29,04%	-134,51%
Earnings per share	-	-	-	-
Interest and investment income	-	-	-	-
Interest expense	-	-	-	-
Net interest expenses	-	-	-	-
Depreciation and amortization charges	-	-	-	-
EBITDA	-	-	-	-
Gain or loss from assets sale	-	-	-	-

Ask anything